DBV Technologies | DBVT - Loan Capital


DBV Technologies reported $0 in Loan Capital for its fiscal quarter ending in March of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
DBV Technologies USD 0 0 Mar/2025
Galectin Therapeutics USD 93.42M 9.08M Jun/2024
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Incyte USD 28.42M 994K Jun/2026
Insmed USD 543.51M 1.3M Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
United Therapeutics USD 100M 100M Jun/2024